Panion’s epilepsy product candidate for gene therapy in the dog: FDA has established an Investigational New Animal Drug (INAD) file.
Panion Animal Health AB (“Panion”) has in Q4-17 requested the FDA to open an Investigational New Animal Drug application file to carry out the development of our new product for use in the dog. Panion plans to develop and gain approval for the use of CG-01-canine, a recombinant adeno-associated virus vector expressing neuropeptide Y and receptor peptide Y2 to treat drug refractory idiopathic epilepsy in the dog via intracranial injection. A summary of the scientific rationale for the therapy and the preliminary work completed to date was submitted and the FDA accepted this with a